DNLI
Denali Therapeutics Inc.
+0.23 (+1.15%)20.29USD385K成交股數3.2B市值–本益比(近四季)899.9股價營收比–營收年增(近四季)2026-11-05下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 5 · 435K · 3 |
| 其中 10b5-1 計畫賣出 | 3 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 435K |
| 近 180 天 淨額 | −435K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-04 | 09-09 | Chin Peter Scott | Chief Medical Officer | S 公開市場賣出 | 1.7K | 22.29 | 37K | 205K | SEC |
| 2026-09-02 | 09-04 | Thornberry Nancy | Director | S 公開市場賣出(10b5-1) | 10.8K | 22.85 | 247K | 20.3K | SEC |
| 2026-09-02 | 09-04 | Thornberry Nancy | Director | S 公開市場賣出(10b5-1) | 615 | 23.74 | 15K | 19.7K | SEC |
| 2026-09-01 | 09-03 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出(10b5-1) | 2.8K | 23.44 | 65K | 279K | SEC |
| 2026-08-12 | 08-14 | Watts Ryan J. | President and CEO | G 贈與 | 32.2K | – | – | 2.1M | SEC |
| 2026-08-11 | 08-13 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出 | 2.9K | 25.07 | 72K | 282K | SEC |
| 2026-06-03 | 06-05 | Klein Peter S | Director | A 獲配股票 | 6.4K | – | – | 33.9K | SEC |
| 2026-06-03 | 06-05 | FLATLEY JAY T | Director | A 獲配股票 | 6.4K | – | – | 22.6K | SEC |
| 2026-06-03 | 06-05 | BAKER BROS. ADVISORS LP | Director | A 獲配股票 | 6.4K | – | – | 3.4M | SEC |
| 2026-06-03 | 06-05 | Krognes Steve E. | Director | A 獲配股票 | 6.4K | – | – | 38.2K | SEC |
| 2026-06-03 | 06-05 | Thornberry Nancy | Director | A 獲配股票 | 6.4K | – | – | 31.1K | SEC |
| 2026-06-03 | 06-05 | Cook Jennifer E. | Director | A 獲配股票 | 6.4K | – | – | 32.5K | SEC |
| 2026-06-03 | 06-05 | Baker Brothers Life Sciences LP | Director | A 獲配股票 | 6.4K | – | – | 343K | SEC |
| 2026-06-03 | 06-05 | Schenkein David P | Director | A 獲配股票 | 6.4K | – | – | 21.7K | SEC |
| 2026-06-03 | 06-05 | BAKER FELIX | Director | A 獲配股票 | 6.4K | – | – | 343K | SEC |
| 2026-06-03 | 06-05 | Baker Bros. Advisors (GP) LLC | Director | A 獲配股票 | 6.4K | – | – | 3.4M | SEC |
| 2026-06-03 | 06-05 | Baker Bros. Advisors (GP) LLC | Director | A 獲配股票 | 6.4K | – | – | 343K | SEC |
| 2026-06-03 | 06-05 | Van Hauwermeiren Timothy | Director | A 獲配股票 | 6.4K | – | – | 17.0K | SEC |
| 2026-06-03 | 06-05 | BAKER JULIAN | Director | A 獲配股票 | 6.4K | – | – | 343K | SEC |
| 2026-06-03 | 06-05 | Baker Brothers Life Sciences LP | Director | A 獲配股票 | 6.4K | – | – | 3.4M | SEC |
| 2026-06-03 | 06-05 | BAKER FELIX | Director | A 獲配股票 | 6.4K | – | – | 3.4M | SEC |
| 2026-06-03 | 06-05 | BAKER BROS. ADVISORS LP | Director | A 獲配股票 | 6.4K | – | – | 343K | SEC |
| 2026-06-03 | 06-05 | BAKER JULIAN | Director | A 獲配股票 | 6.4K | – | – | 3.4M | SEC |
| 2026-06-03 | 06-05 | 667, L.P. | Director | A 獲配股票 | 6.4K | – | – | 3.4M | SEC |
| 2026-06-03 | 06-05 | 667, L.P. | Director | A 獲配股票 | 6.4K | – | – | 343K | SEC |
| 2026-01-06 | 01-08 | Watts Ryan J. | President and CEO | S 公開市場賣出 | 35.2K | 16.50 | 581K | 297K | SEC |
| 2026-01-06 | 01-08 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出 | 17.2K | 16.50 | 284K | 283K | SEC |
| 2026-01-03 | 01-05 | Schuth Alexander O. | COFO and Secretary | A 獲配股票 | 57.7K | – | – | 300K | SEC |
| 2026-01-03 | 01-05 | Watts Ryan J. | President and CEO | A 獲配股票 | 79.0K | – | – | 332K | SEC |
| 2025-11-04 | 11-06 | Van Hauwermeiren Timothy | Director | A 獲配股票 | 10.6K | – | – | 10.6K | SEC |
| 2025-09-03 | 09-05 | Watts Ryan J. | President and CEO | G 贈與 | 50.0K | – | – | 2.2M | SEC |
| 2025-08-13 | 08-14 | Ho Carole | Chief Medical Officer | S 公開市場賣出(10b5-1) | 806 | 14.64 | 12K | 217K | SEC |
| 2025-08-12 | 08-14 | Ho Carole | Chief Medical Officer | S 公開市場賣出(10b5-1) | 2.9K | 13.58 | 40K | 217K | SEC |
| 2025-08-12 | 08-14 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出 | 2.9K | 13.58 | 40K | 242K | SEC |
| 2025-08-05 | 08-07 | Ho Carole | Chief Medical Officer | M 選擇權執行 | 44.7K | 0.68 | 30K | 220K | SEC |
| 2025-07-09 | 07-11 | Watts Ryan J. | President and CEO | M 選擇權執行 | 455K | 0.68 | 310K | 708K | SEC |
| 2025-07-09 | 07-11 | Watts Ryan J. | President and CEO | S 公開市場賣出(10b5-1) | 495K | 15.00 | 7.4M | 253K | SEC |
| 2025-07-09 | 07-11 | Watts Ryan J. | President and CEO | M 選擇權執行 | 40.0K | 5.28 | 211K | 748K | SEC |
| 2025-06-03 | 06-05 | BAKER JULIAN | Director | A 獲配股票 | 10.6K | – | – | 337K | SEC |
| 2025-06-03 | 06-05 | Cook Jennifer E. | Director | A 獲配股票 | 6.0K | – | – | 26.1K | SEC |
| 2025-06-03 | 06-05 | FLATLEY JAY T | Director | A 獲配股票 | 6.0K | – | – | 16.2K | SEC |
| 2025-06-03 | 06-05 | 667, L.P. | Director | A 獲配股票 | 10.6K | – | – | 3.4M | SEC |
| 2025-06-03 | 06-05 | Krognes Steve E. | Director | A 獲配股票 | 6.0K | – | – | 31.8K | SEC |
| 2025-06-03 | 06-05 | Schenkein David P | Director | A 獲配股票 | 6.0K | – | – | 15.3K | SEC |
| 2025-06-03 | 06-05 | Thornberry Nancy | Director | A 獲配股票 | 6.0K | – | – | 24.7K | SEC |
| 2025-06-03 | 06-05 | Tessier-Lavigne Marc | Director | A 獲配股票 | 6.0K | – | – | 1.9M | SEC |
| 2025-06-03 | 06-05 | Baker Bros. Advisors (GP) LLC | Director | A 獲配股票 | 10.6K | – | – | 3.4M | SEC |
| 2025-06-03 | 06-05 | Baker Bros. Advisors (GP) LLC | Director | A 獲配股票 | 10.6K | – | – | 337K | SEC |
| 2025-06-03 | 06-05 | 667, L.P. | Director | A 獲配股票 | 10.6K | – | – | 337K | SEC |
| 2025-06-03 | 06-05 | Baker Brothers Life Sciences LP | Director | A 獲配股票 | 10.6K | – | – | 3.4M | SEC |
| 2025-06-03 | 06-05 | Baker Brothers Life Sciences LP | Director | A 獲配股票 | 10.6K | – | – | 337K | SEC |
| 2025-06-03 | 06-05 | BAKER BROS. ADVISORS LP | Director | A 獲配股票 | 10.6K | – | – | 3.4M | SEC |
| 2025-06-03 | 06-05 | BAKER BROS. ADVISORS LP | Director | A 獲配股票 | 10.6K | – | – | 337K | SEC |
| 2025-06-03 | 06-05 | Klein Peter S | Director | A 獲配股票 | 6.0K | – | – | 27.5K | SEC |
| 2025-06-03 | 06-05 | BAKER FELIX | Director | A 獲配股票 | 10.6K | – | – | 3.4M | SEC |
| 2025-06-03 | 06-05 | BAKER FELIX | Director | A 獲配股票 | 10.6K | – | – | 337K | SEC |
| 2025-06-03 | 06-05 | BAKER JULIAN | Director | A 獲配股票 | 10.6K | – | – | 3.4M | SEC |
| 2025-01-07 | 01-08 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出 | 2.9K | 20.81 | 60K | 244K | SEC |
| 2025-01-07 | 01-08 | Watts Ryan J. | President and CEO | S 公開市場賣出 | 7.7K | 20.81 | 159K | 253K | SEC |
| 2025-01-07 | 01-08 | Krognes Steve E. | Director | S 公開市場賣出 | 3.3K | 20.81 | 69K | 25.8K | SEC |
| 2025-01-07 | 01-08 | Ho Carole | Chief Medical Officer | S 公開市場賣出 | 2.9K | 20.81 | 60K | 176K | SEC |
| 2025-01-06 | 01-08 | Ho Carole | Chief Medical Officer | S 公開市場賣出 | 12.3K | 20.22 | 248K | 179K | SEC |
| 2025-01-06 | 01-08 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出 | 12.3K | 20.22 | 248K | 247K | SEC |
| 2025-01-06 | 01-08 | Watts Ryan J. | President and CEO | S 公開市場賣出 | 29.3K | 20.22 | 592K | 261K | SEC |
| 2025-01-03 | 01-07 | Schuth Alexander O. | COFO and Secretary | A 獲配股票 | 54.2K | – | – | 259K | SEC |
| 2025-01-03 | 01-07 | Ho Carole | Chief Medical Officer | A 獲配股票 | 54.2K | – | – | 191K | SEC |
| 2025-01-03 | 01-07 | Watts Ryan J. | President and CEO | A 獲配股票 | 54.2K | – | – | 290K | SEC |
| 2025-01-02 | 01-03 | SATO VICKI L | Director | S 公開市場賣出(10b5-1) | 3.1K | 20.91 | 64K | 108K | SEC |
| 2024-12-31 | 01-03 | Krognes Steve E. | Director | S 公開市場賣出(10b5-1) | 30.0K | 20.25 | 608K | 29.1K | SEC |
| 2024-12-27 | 12-31 | Schuth Alexander O. | COFO and Secretary | M 選擇權執行 | 6.7K | 5.28 | 35K | 205K | SEC |
| 2024-11-25 | 11-27 | Ho Carole | Chief Medical Officer | M 選擇權執行 | 17.8K | 0.68 | 12K | 137K | SEC |
| 2024-11-22 | 11-26 | Schuth Alexander O. | COFO and Secretary | M 選擇權執行 | 20.5K | 0.68 | 14K | 199K | SEC |
| 2024-11-11 | 11-13 | Schenkein David P | Director | S 公開市場賣出(10b5-1) | 32.3K | 32.87 | 1.1M | 9.2K | SEC |
| 2024-11-11 | 11-13 | Schenkein David P | Director | S 公開市場賣出(10b5-1) | 27.1K | 32.09 | 871K | 41.5K | SEC |
| 2024-11-11 | 11-13 | Schenkein David P | Director | M 選擇權執行 | 47.2K | 18.00 | 849K | 68.7K | SEC |
| 2024-11-07 | 11-12 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出(10b5-1) | 300 | 31.29 | 9K | 178K | SEC |
| 2024-11-07 | 11-12 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出(10b5-1) | 2.9K | 30.72 | 90K | 178K | SEC |
| 2024-11-07 | 11-12 | Schuth Alexander O. | COFO and Secretary | S 公開市場賣出(10b5-1) | 12.3K | 29.68 | 366K | 181K | SEC |
| 2024-11-07 | 11-12 | Schuth Alexander O. | COFO and Secretary | M 選擇權執行 | 15.6K | 5.28 | 82K | 194K | SEC |
| 2024-11-07 | 11-12 | SATO VICKI L | Director | S 公開市場賣出(10b5-1) | 1.0K | 30.00 | 31K | 111K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| BlackRock, Inc. | 14.0M | 361M | 新進 | 新進 |
| BAILLIE GIFFORD & CO | 12.0M | 308M | 新進 | 新進 |
| STATE STREET CORP | 7.0M | 181M | 新進 | 新進 |
| Temasek Holdings (Private) Ltd | 7.0M | 180M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.5M | 167M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.3M | 161M | 新進 | 新進 |
| FMR LLC | 4.5M | 117M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 4.2M | 107M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.0M | 102M | 新進 | 新進 |
| Holocene Advisors, LP | 3.9M | 100M | 新進 | 新進 |
| BAKER BROS. ADVISORS LP | 3.7M | 96.0M | 新進 | 新進 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.2M | 81.3M | 新進 | 新進 |
| UBS Group AG | 3.1M | 80.3M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 2.9M | 73.6M | 新進 | 新進 |
| 挪威主權基金 NORGES BANK | 2.8M | 72.7M | 新進 | 新進 |
| Pictet Asset Management Holding SA | 2.8M | 71.9M | 新進 | 新進 |
| Capital Research Global Investors | 2.6M | 66.0M | 新進 | 新進 |
| Fisher Asset Management, LLC | 2.4M | 62.1M | 新進 | 新進 |
| ALLIANCEBERNSTEIN L.P. | 3.0M | 57.3M | 新進 | 新進 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.2M | 56.8M | 新進 | 新進 |
| Casdin Capital, LLC | 2.0M | 52.6M | 新進 | 新進 |
| Crestline Management, L.P. | 1.9M | 49.1M | 新進 | 新進 |
| PRINCIPAL FINANCIAL GROUP INC | 1.4M | 36.5M | 新進 | 新進 |
| Foresite Capital Management VI LLC | 1.4M | 35.9M | 新進 | 新進 |
| Siren, L.L.C. | 1.4M | 35.9M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 293 +24 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 293 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 156M · 97.7% |
| 合計季末市值 | 3.5B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 16.6M |
|---|---|
| 與上期比 | -7.3% |
| 佔流通股數 | 10.41% |
| 日均成交量 | 951K |
| 回補天數 | 17.5 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 16.6M | -7.3% | 10.41% | 951K | 17.5 |
| 2026-08-14 | 18.0M | +3.0% | 11.24% | 1.4M | 12.4 |
| 2026-07-31 | 17.4M | +8.7% | 10.91% | 1.4M | 12.1 |
| 2026-07-15 | 16.0M | +0.5% | 10.03% | 1.9M | 8.4 |
| 2026-06-30 | 15.9M | +3.5% | 9.98% | 2.3M | 7.0 |
| 2026-06-15 | 15.4M | +2.8% | 9.64% | 1.8M | 8.4 |
| 2026-05-29 | 15.0M | +6.9% | 9.38% | 1.9M | 8.0 |
| 2026-05-15 | 14.0M | -5.3% | 8.78% | 1.9M | 7.5 |
| 2026-04-30 | 14.8M | -3.1% | 9.27% | 1.5M | 10.0 |
| 2026-04-15 | 15.3M | -0.9% | 9.56% | 1.4M | 11.0 |
| 2026-03-31 | 15.4M | +8.2% | 9.65% | 2.3M | 6.7 |
| 2026-03-13 | 14.3M | -0.4% | 8.92% | 1.5M | 9.5 |
| 2026-02-27 | 14.3M | +5.3% | 8.96% | 1.6M | 9.0 |
| 2026-02-13 | 13.6M | +0.3% | 8.50% | 1.6M | 8.7 |
| 2026-01-30 | 13.6M | -8.8% | 8.48% | 1.9M | 7.0 |
| 2026-01-15 | 14.9M | +2.0% | 9.30% | 1.5M | 9.7 |
| 2025-12-31 | 14.6M | +11.2% | 9.11% | 1.2M | 12.5 |
| 2025-12-15 | 13.1M | +0.9% | 8.19% | 2.1M | 6.2 |
| 2025-11-28 | 13.0M | -7.4% | 8.12% | 1.3M | 10.1 |
| 2025-11-14 | 14.0M | +6.9% | 8.77% | 1.5M | 9.1 |
| 2025-10-31 | 13.1M | -9.8% | 8.20% | 1.5M | 8.9 |
| 2025-10-15 | 14.5M | +2.7% | 9.09% | 1.7M | 8.5 |
| 2025-09-30 | 14.2M | +8.2% | 8.85% | 2.5M | 5.7 |
| 2025-09-15 | 13.1M | -4.8% | 8.18% | 2.4M | 5.5 |
| 2025-08-29 | 13.7M | +2.0% | 8.60% | 1.6M | 8.5 |
| 2025-08-15 | 13.5M | +5.0% | 8.43% | 1.9M | 7.0 |